These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15883754)

  • 1. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts.
    Hirata A; Minamino T; Asanuma H; Sanada S; Fujita M; Tsukamoto O; Wakeno M; Myoishi M; Okada K; Koyama H; Komamura K; Takashima S; Shinozaki Y; Mori H; Tomoike H; Hori M; Kitakaze M
    Cardiovasc Drugs Ther; 2005 Jan; 19(1):33-40. PubMed ID: 15883754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myocardial reperfusion injury management: erythropoietin compared with postconditioning.
    Tamareille S; Ghaboura N; Treguer F; Khachman D; Croué A; Henrion D; Furber A; Prunier F
    Am J Physiol Heart Circ Physiol; 2009 Dec; 297(6):H2035-43. PubMed ID: 19617412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling.
    Ghaboura N; Tamareille S; Ducluzeau PH; Grimaud L; Loufrani L; Croué A; Tourmen Y; Henrion D; Furber A; Prunier F
    Basic Res Cardiol; 2011 Jan; 106(1):147-62. PubMed ID: 20981553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte colony-stimulating factor mediates cardioprotection against ischemia/reperfusion injury via phosphatidylinositol-3-kinase/Akt pathway in canine hearts.
    Takahama H; Minamino T; Hirata A; Ogai A; Asanuma H; Fujita M; Wakeno M; Tsukamoto O; Okada K; Komamura K; Takashima S; Shinozaki Y; Mori H; Mochizuki N; Kitakaze M
    Cardiovasc Drugs Ther; 2006 Jun; 20(3):159-65. PubMed ID: 16775664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium.
    Hamid SA; Bower HS; Baxter GF
    Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2598-606. PubMed ID: 17220176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin (EPO) affords more potent cardioprotection by activation of distinct signaling to mitochondrial kinases compared with carbamylated EPO.
    Sato T; Tanno M; Miki T; Yano T; Sato T; Shimamoto K; Miura T
    Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):401-8. PubMed ID: 20953685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling.
    Hanlon PR; Fu P; Wright GL; Steenbergen C; Arcasoy MO; Murphy E
    FASEB J; 2005 Aug; 19(10):1323-5. PubMed ID: 15946993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism.
    Xu X; Cao Z; Cao B; Li J; Guo L; Que L; Ha T; Chen Q; Li C; Li Y
    Surgery; 2009 Sep; 146(3):506-14. PubMed ID: 19715808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limitation of infarct size by erythropoietin is associated with translocation of Akt to the mitochondria after reperfusion.
    Kobayashi H; Miura T; Ishida H; Miki T; Tanno M; Yano T; Sato T; Hotta H; Shimamoto K
    Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):812-9. PubMed ID: 18346168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone-induced myocardial protection against ischaemia-reperfusion injury is mediated via a phosphatidylinositol 3-kinase/Akt-dependent pathway.
    Zhang XJ; Xiong ZB; Tang AL; Ma H; Ma YD; Wu JG; Dong YG
    Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):156-61. PubMed ID: 19566839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Darbepoetin alfa protects the rat heart against infarction: dose-response, phase of action, and mechanisms.
    Baker JE; Kozik D; Hsu AK; Fu X; Tweddell JS; Gross GJ
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):337-45. PubMed ID: 17577097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway.
    Okumura H; Nagaya N; Itoh T; Okano I; Hino J; Mori K; Tsukamoto Y; Ishibashi-Ueda H; Miwa S; Tambara K; Toyokuni S; Yutani C; Kangawa K
    Circulation; 2004 Jan; 109(2):242-8. PubMed ID: 14691041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling.
    Jonassen AK; Sack MN; Mjøs OD; Yellon DM
    Circ Res; 2001 Dec; 89(12):1191-8. PubMed ID: 11739285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta.
    Nishihara M; Miura T; Miki T; Sakamoto J; Tanno M; Kobayashi H; Ikeda Y; Ohori K; Takahashi A; Shimamoto K
    Am J Physiol Heart Circ Physiol; 2006 Aug; 291(2):H748-55. PubMed ID: 16565311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H(2) mediates cardioprotection via involvements of K(ATP) channels and permeability transition pores of mitochondria in dogs.
    Yoshida A; Asanuma H; Sasaki H; Sanada S; Yamazaki S; Asano Y; Shinozaki Y; Mori H; Shimouchi A; Sano M; Asakura M; Minamino T; Takashima S; Sugimachi M; Mochizuki N; Kitakaze M
    Cardiovasc Drugs Ther; 2012 Jun; 26(3):217-26. PubMed ID: 22527618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin protects isolated hearts from ischemia/reperfusion injury: cross-talk between PI3-K/Akt and JNKs.
    Liu HT; Zhang HF; Si R; Zhang QJ; Zhang KR; Guo WY; Wang HC; Gao F
    Sheng Li Xue Bao; 2007 Oct; 59(5):651-9. PubMed ID: 17940706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotection by epsilon-protein kinase C activation from ischemia: continuous delivery and antiarrhythmic effect of an epsilon-protein kinase C-activating peptide.
    Inagaki K; Begley R; Ikeno F; Mochly-Rosen D
    Circulation; 2005 Jan; 111(1):44-50. PubMed ID: 15611364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin protects the heart from ventricular arrhythmia during ischemia and reperfusion via neuronal nitric-oxide synthase.
    Burger DE; Xiang FL; Hammoud L; Jones DL; Feng Q
    J Pharmacol Exp Ther; 2009 Jun; 329(3):900-7. PubMed ID: 19307451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.
    Prunier F; Bière L; Gilard M; Boschat J; Mouquet F; Bauchart JJ; Charbonnier B; Genée O; Guérin P; Warin-Fresse K; Durand E; Lafont A; Christiaens L; Abi-Khalil W; Delépine S; Benard T; Furber A
    Am Heart J; 2012 Feb; 163(2):200-7.e1. PubMed ID: 22305837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro.
    Bullard AJ; Yellon DM
    Cardiovasc Drugs Ther; 2005 Oct; 19(5):333-6. PubMed ID: 16382295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.